Karo Pharma

    OverviewSuggest Edit

    Karo Pharma is a healthcare company, which develops and markets products for pharmacies and the health care sectors. The Company's development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include medical compression socks, nutritional products, ergonomic products for people with disabilities, and medicine storage products. The Company also offers medicines for the treatment of sore throats, vaginal dryness, pains, etc. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases, compounds to treat multiple sclerosis and cancer, and a common cold spray.

    TypePublic
    Founded1987
    HQStockholm, SE
    Websitekaropharma.com

    Latest Updates

    Employees (est.) (Feb 2019)80

    Key People/Management at Karo Pharma

    Anders Lönner

    Anders Lönner

    Board Member and Chairman Since 2014.

    Karo Pharma Office Locations

    Karo Pharma has an office in Stockholm
    Stockholm, SE (HQ)
    Nybrokajen 7
    Show all (2)

    Karo Pharma Online and Social Media Presence

    Embed Graph

    Karo Pharma News and Updates

    Karo Pharma buys Swedish consumer healthcare firm Trimb

    Karo Pharma AB has acquired Trimb, a Swedish consumer healthcare company, for about $366 million. The deal is expected to close before the end of the year. Trimb was backed by Avista Capital Partners.

    Avista Capital Partners To Sell Trimb To Karo Pharma

    NEW YORK and STOCKHOLM, June 25, 2019 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused on growth-oriented healthcare businesses, today announced that Karo Pharma AB (publ) (the "Company" or "Karo Pharma"), a specialty pharma company, has acquired...

    Karo Pharma publishes the 2018 annual report

    Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com).read more

    Karo Pharma Blogs

    INTERIM REPORT JANUARY – SEPTEMBER 2019

    JULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the period, of which the acquired operations account for 10% (MSEK 41.0). · Adjusted EBITDA amounted to MSEK 156.9 (145.8) excluding non-recurring items, costs related to the acquisition of Trimb …

    New number of shares and votes in Karo Pharma

    As previously announced, Karo Pharma Aktiebolag (“Karo Pharma”) has completed a rights issue of 60,700,422 shares, with the purpose of repaying a part of the financing of Karo Pharma’s acquisition of Trimb Holding AB as well as to strengthen Karo Pharma’s financial capacity to carry out acquisitions…

    Karo Pharma’s rights issue fully subscribed

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. T…

    Karo Pharma postpones publication of the interim report for the period January – September 2019

    The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the publication of the interim report for the period January – September 2019 to 15 November 2019. The previously announced date for publication was 1 November 2019. The delay is due to the ongoing integration …

    Karo Pharma publishes prospectus relating to the rights issue

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. T…

    Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2 billion

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. T…
    Show more

    Karo Pharma Frequently Asked Questions

    • When was Karo Pharma founded?

      Karo Pharma was founded in 1987.

    • Who are Karo Pharma key executives?

      Karo Pharma's key executives are Anders Lönner.

    • How many employees does Karo Pharma have?

      Karo Pharma has 80 employees.

    • Who are Karo Pharma competitors?

      Competitors of Karo Pharma include MolMed, Innocare and Sareum Holdings.

    • Where is Karo Pharma headquarters?

      Karo Pharma headquarters is located at Nybrokajen 7, Stockholm.

    • Where are Karo Pharma offices?

      Karo Pharma has an office in Stockholm.

    • How many offices does Karo Pharma have?

      Karo Pharma has 2 offices.